RNS Number:1124F
Inion Oy
26 June 2006

          Inion Appoints Seppo Nevalainen as General Manager - Tampere

            Experienced Medical Device Professional Joins Executive
                                 Management Team


Tampere, Finland, 26th June 2006. Inion (LSE: IIN.L), a Finnish company focused
on the development of novel biodegradable medical implants, is pleased to
announce that Seppo Nevalainen has been appointed as General Manager- Tampere,
where he will be responsible for all of the company's operations. Inion's site
in Tampere is at the centre of the company's business carrying out R&D,
marketing, manufacturing, logistics, customer support as well as certain quality
and IT, financial and legal functions. Mr Nevalainen will be a member of the
Executive Management Team and report to Dr Auvo Kaikkonen, Inion's CEO.

Mr Nevalainen has spent the last 19 years working in the medical devices
industry and most recently, he was General Manager for GE Healthcare, formerly
Intrumentarium, Life Support Division of Europe, Middle-East and Africa, a
company focused on the anaesthesia and critical care markets. Mr Nevalainen is
an experienced marketing business professional who has managed a number
multi-functional organisations focused on developing and supporting a network of
international distributors.

Commenting on Mr Nevalainen's appointment, Dr Auvo Kaikkonen, Inion CEO said: 
"We are very pleased to welcome Seppo to the team. His many years of business
experience in the medical device industry, combined with his operational
management expertise and leadership skills will ensure that he plays a key role
in the development of Inion's business."

Seppo Nevalainen commented, "Inion has an exciting future based on its
biodegradable medical implant technology. I am looking forward to using my
international medical business experience to successfully manage the company's
operations in Tampere and to further develop cooperation between the company's
distributor and partner network. These are two key activities which are central
to Inion becoming a highly successful and profitable business."


                                     -Ends-


For further information, please contact:

Inion Oy
Dr Auvo Kaikkonen, Chief Executive Officer             Tel: +358 3 230 6600
                                                       Tel: +44 (0)1279 874 222

Citigate Dewe Rogerson                                 Tel: +44 (0)207 638 9571
Mark Swallow / David Dible / Helena Galilee


About Inion (www.inion.com)

Inion Oy is a Finnish company that specializes in the development of
biodegradable medical implants.

The Inion core expertise and technology lies in the design and manufacture of
innovative biodegradable plates, screws, pins and membranes that are used to
enhance the healing of skeletal injuries (bone and soft tissue), such as those
caused by trauma or by reconstructive surgery. Inion implants are made from its
proprietary Inion Optima(TM) family of biomaterials, with properties tailored
for specific surgical applications, in terms of strength, flexibility and rate
of degradation.

Inion has developed and launched products in five strategic business areas -
cranio-maxillofacial surgery, orthopaedic trauma, sports medicine, dental
surgery and most recently in the spinal implant area - in nearly 50 countries
worldwide.

Inion was incorporated in early 2000 by an international team of experts in
biodegradable materials and their clinical applications, and listed on the
Official List of the UK Listing Authority in December 2004. The Company's has
operations in the UK, R&D and production facilities in Tampere, Finland, and a
US office in Oklahoma City, OK.

This announcement includes "forward-looking statements" which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Group's products), and any statements
preceded by, followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions
or the negative thereof. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or achievements of the
Group to be materially different from future results, performance or
achievements expressed or implied by such forward-looking statements. Such
forward-looking statements are based on numerous assumptions regarding the
Group's present and future business strategies and the environment in which the
Group will operate in the future. Among the important factors that could cause
the Group's actual results, performance or achievements to differ materially
from those in forward-looking statements include those relating to Inion's
funding requirements, regulatory approvals, reliance on third parties,
intellectual property, key personnel and other factors. These forward-looking
statements speak only as at the date of this announcement. The Group expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained in this announcement to reflect any
change in the Group's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result
of these factors, prospective investors are cautioned not to rely on any
forward-looking statement.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCEAKKDAASKEFE
Inion Oy (LSE:IIN)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Inion Oy Charts.
Inion Oy (LSE:IIN)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Inion Oy Charts.